Literature DB >> 24975128

Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events.

Robert J Mentz1, Samuel Broderick, Linda K Shaw, Karen Chiswell, Mona Fiuzat, Christopher M O'Connor.   

Abstract

AIMS: The impact of refractory angina pectoris (AP) in patients with ischaemic cardiomyopathy (ICM) is unknown. We investigated the characteristics and outcomes of ICM patients with persistent AP following cardiac catheterization. METHODS AND
RESULTS: Patients who underwent coronary angiography at Duke from 2000 to 2009 with an EF <40% and ICM with persistent AP were compared with similar patients without persistent AP. Persistent AP was defined by patient report of ischaemic symptoms within 1 year of index catheterization. Time-to-event was examined using Kaplan-Meier or cumulative incidence and Cox proportional hazards modelling methods for death/myocardial infarction (MI)/revascularization [i.e. major adverse cardiac events (MACE)], death/MI, death, and cardiovascular death/hospitalization. Of 965 ICM patients, 298 (31%) had persistent AP. These patients were younger and had more previous revascularization than patients without persistent AP. Both groups had high use of aspirin, beta-blockers, ACE inhibitors, and statins, but modest nitrate use. Over a median follow-up of >5 years, patients with persistent AP had increased rates of MACE, and cardiovascular death/hospitalization compared with patients without persistent AP [5-year cumulative event rates of 53% vs. 46% (P = 0.013) and 73% vs. 60% (P < 0.0001), respectively], but similar rates of death (P = 0.59) and death/MI (P = 0.50). After multivariable adjustment, persistent AP remained associated with increased MACE [hazard ratio (HR) 1.30; 95% confidence interval (CI) 1.08-1.57], and cardiovascular death/hospitalization (HR 1.36; 95% CI 1.14-1.62).
CONCLUSION: Persistent AP is common despite medical therapy in patients with ICM and is independently associated with increased long-term MACE and rehospitalization. Future prospective studies of persistent AP in ICM patients are warranted.
© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.

Entities:  

Keywords:  Heart failure; Outcomes; Persistent angina pectoris

Mesh:

Year:  2014        PMID: 24975128      PMCID: PMC5702887          DOI: 10.1002/ejhf.130

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  15 in total

1.  2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina.

Authors:  Theodore D Fraker; Stephan D Fihn; Raymond J Gibbons; Jonathan Abrams; Kanu Chatterjee; Jennifer Daley; Prakash C Deedwania; John S Douglas; T Bruce Ferguson; Julius M Gardin; Robert A O'Rourke; Richard C Pasternak; Sankey V Williams; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Christopher E Buller; Mark A Creager; Steven M Ettinger; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel; Lynn G Tarkington; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2007-12-04       Impact factor: 24.094

2.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Authors:  Gilles Montalescot; Udo Sechtem; Stephan Achenbach; Felicita Andreotti; Chris Arden; Andrzej Budaj; Raffaele Bugiardini; Filippo Crea; Thomas Cuisset; Carlo Di Mario; J Rafael Ferreira; Bernard J Gersh; Anselm K Gitt; Jean-Sebastien Hulot; Nikolaus Marx; Lionel H Opie; Matthias Pfisterer; Eva Prescott; Frank Ruschitzka; Manel Sabaté; Roxy Senior; David Paul Taggart; Ernst E van der Wall; Christiaan J M Vrints; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Juhani Knuuti; Marco Valgimigli; Héctor Bueno; Marc J Claeys; Norbert Donner-Banzhoff; Cetin Erol; Herbert Frank; Christian Funck-Brentano; Oliver Gaemperli; José R Gonzalez-Juanatey; Michalis Hamilos; David Hasdai; Steen Husted; Stefan K James; Kari Kervinen; Philippe Kolh; Steen Dalby Kristensen; Patrizio Lancellotti; Aldo Pietro Maggioni; Massimo F Piepoli; Axel R Pries; Francesco Romeo; Lars Rydén; Maarten L Simoons; Per Anton Sirnes; Ph Gabriel Steg; Adam Timmis; William Wijns; Stephan Windecker; Aylin Yildirir; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

3.  Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS).

Authors:  P Hjemdahl; S V Eriksson; C Held; L Forslund; P Näsman; N Rehnqvist
Journal:  Heart       Date:  2005-06-10       Impact factor: 5.994

4.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher; Jeroen J Bax; Helmut Baumgartner; Claudio Ceconi; Veronica Dean; Christi Deaton; Robert Fagard; Christian Funck-Brentano; David Hasdai; Arno Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Theresa McDonagh; Cyril Moulin; Bogdan A Popescu; Zeljko Reiner; Udo Sechtem; Per Anton Sirnes; Michal Tendera; Adam Torbicki; Alec Vahanian; Stephan Windecker; Theresa McDonagh; Udo Sechtem; Luis Almenar Bonet; Panayiotis Avraamides; Hisham A Ben Lamin; Michele Brignole; Antonio Coca; Peter Cowburn; Henry Dargie; Perry Elliott; Frank Arnold Flachskampf; Guido Francesco Guida; Suzanna Hardman; Bernard Iung; Bela Merkely; Christian Mueller; John N Nanas; Olav Wendelboe Nielsen; Stein Orn; John T Parissis; Piotr Ponikowski
Journal:  Eur J Heart Fail       Date:  2012-08       Impact factor: 15.534

5.  A standardized definition of ischemic cardiomyopathy for use in clinical research.

Authors:  G Michael Felker; Linda K Shaw; Christopher M O'Connor
Journal:  J Am Coll Cardiol       Date:  2002-01-16       Impact factor: 24.094

6.  The Heart Failure Revascularisation Trial (HEART).

Authors:  John G F Cleland; Melanie Calvert; Nick Freemantle; Yvonne Arrow; Stephen G Ball; Robert S Bonser; Sudipta Chattopadhyay; Michael S Norell; Dudley J Pennell; Roxy Senior
Journal:  Eur J Heart Fail       Date:  2010-12-13       Impact factor: 15.534

Review 7.  Learning from recent trials and shaping the future of acute heart failure trials.

Authors:  Robert J Mentz; Gary Michael Felker; Tariq Ahmad; William Frank Peacock; Bertram Pitt; Mona Fiuzat; Aldo P Maggioni; Mihai Gheorghiade; Yuki Ando; Stuart J Pocock; Faiez Zannad; Christopher M O'Connor
Journal:  Am Heart J       Date:  2013-09-13       Impact factor: 4.749

8.  Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty.

Authors:  D B Mark; C L Nelson; R M Califf; F E Harrell; K L Lee; R H Jones; D F Fortin; R S Stack; D D Glower; L R Smith
Journal:  Circulation       Date:  1994-05       Impact factor: 29.690

9.  Heart failure-related hospitalization in the U.S., 1979 to 2004.

Authors:  Jing Fang; George A Mensah; Janet B Croft; Nora L Keenan
Journal:  J Am Coll Cardiol       Date:  2008-08-05       Impact factor: 24.094

10.  Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death.

Authors:  P J Harris; K L Lee; F E Harrell; V S Behar; R A Rosati
Journal:  Circulation       Date:  1980-10       Impact factor: 29.690

View more
  4 in total

Review 1.  Prediction of Post Percutaneous Coronary Intervention Myocardial Ischaemia.

Authors:  Alda Huqi; Giacinta Guarini; Doralisa Morrone; Mario Marzilli
Journal:  Eur Cardiol       Date:  2016-12

2.  Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.

Authors:  Robert J Mentz; Jonathan Buggey; Mona Fiuzat; Mads K Ersbøll; Phillip J Schulte; Adam D DeVore; Eric L Eisenstein; Kevin J Anstrom; Christopher M OʼConnor; Eric J Velazquez
Journal:  J Cardiovasc Pharmacol       Date:  2015-05       Impact factor: 3.105

3.  Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION).

Authors:  Kishan S Parikh; Adrian Coles; Phillip J Schulte; William E Kraus; Jerome L Fleg; Steven J Keteyian; Ileana L Piña; Mona Fiuzat; David J Whellan; Christopher M O'Connor; Robert J Mentz
Journal:  Am J Cardiol       Date:  2016-07-29       Impact factor: 2.778

4.  Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH.

Authors:  E Marc Jolicœur; Allison Dunning; Serenella Castelvecchio; Rafal Dabrowski; Myron A Waclawiw; Mark C Petrie; Ralph Stewart; Pardeep S Jhund; Patrice Desvigne-Nickens; Julio A Panza; Robert O Bonow; Benjamin Sun; Tan Ru San; Hussein R Al-Khalidi; Jean L Rouleau; Eric J Velazquez; John G F Cleland
Journal:  J Am Coll Cardiol       Date:  2015-11-10       Impact factor: 24.094

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.